Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall‐cell lung …
YJ Lee, HJ Choi, SK Kim, J Chang… - … Journal of the …, 2010 - Wiley Online Library
BACKGROUND: We investigated the risk of central nervous system (CNS) failure after
clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) …
clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) …
The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR …
S Heon, BY Yeap, NI Lindeman, VA Joshi… - Clinical Cancer …, 2012 - AACR
Purpose: This retrospective study was undertaken to investigate the impact of initial gefitinib
or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of …
or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of …
[HTML][HTML] Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR …
MX Li, H He, ZH Ruan, YX Zhu, RQ Li, X He, BH Lan… - BMC cancer, 2017 - Springer
Background Central nervous system (CNS) brain metastasis of advanced non-small cell
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …
[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
Background Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and …
A Hata, N Katakami, H Yoshioka, J Takeshita… - Anticancer …, 2015 - ar.iiarjournals.org
Aim: The aim of the present study was to investigate the prognostic impact of central nervous
system metastases (CNS) after acquired resistance to epidermal growth factor receptor …
system metastases (CNS) after acquired resistance to epidermal growth factor receptor …
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or …
S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin… - Clinical cancer …, 2010 - AACR
Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
M Takeda, I Okamoto, J Tsurutani, N Oiso… - Japanese journal of …, 2012 - academic.oup.com
Objective Somatic mutations in the epidermal growth factor receptor gene are associated
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
T Shukuya, T Takahashi, T Naito, R Kaira, A Ono… - Lung Cancer, 2011 - Elsevier
INTRODUCTION: Based on previous reports, patients who experience isolated central
nervous system (CNS) failure may not have systemic acquired resistance to EGFR-TKI …
nervous system (CNS) failure may not have systemic acquired resistance to EGFR-TKI …
[HTML][HTML] The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small …
JH Lin, D Lin, L Xu, Q Wang, HH Hu, HP Xu, ZY He - Oncotarget, 2017 - ncbi.nlm.nih.gov
Objective This study aimed to examine the association of clinical prognostic factors with
epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced …
epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced …
Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis …
Y Zhou, B Wang, J Qu, F Yu, Y Zhao, S Li, Y Zeng… - Lung Cancer, 2020 - Elsevier
Objectives Central nervous system (CNS) metastases are common complications in
epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) …